Table 1 Baseline characteristics of the patient population
Characteristic | Stratum 1 (n = 16) | Stratum 2 (n = 8) | Stratum 3 (n = 2) | Overall (n = 26) |
|---|---|---|---|---|
Gender, n (%) | ||||
Male | 5 (31.3) | 7 (87.5) | 1 (50.0) | 13 (50.0) |
Female | 11 (68.8) | 1 (12.5) | 1 (50.0) | 13 (50.0) |
Age, years | ||||
Median (range) | 61.0 (40–74) | 70.0 (58–83) | 66.0 (59–73) | 63.0 (40–83) |
ECOG, n (%) | ||||
0 | 5 (31.3) | 0 | 2 (100.0) | 7 (26.9) |
1 | 11 (68.8) | 8 (100.0) | 0 | 19 (73.1) |
NSCLC duration at baseline, days | ||||
Median (range) | 131.0 (99–482) | 117.0 (92–762) | 167.0 (141–193) | 123.5 (92–762) |
Previous first-line chemotherapy | ||||
Yes, n (%) | 16 (100.0) | 8 (100.0) | 0 | 24 (92.3) |
No, n (%) | 0 | 0 | 2 (100.0) | 2 (7.7) |
Treatment response,a n (%) | ||||
CR | 0 | 0 | – | 0 |
PR | 9 (56.3) | 3 (37.5) | – | 12 (46.2) |
SD | 7 (43.8) | 5 (62.5) | – | 12 (46.2) |
PD | 0 | 0 | – | 0 |
NE | 0 | 0 | – | 0 |
Previous EGFR-TKI therapy | ||||
Yes, n (%) | 0 | 0 | 2 (100.0) | 2 (7.7) |
No, n (%) | 16 (100.0) | 8 (100.0) | 0 | 24 (92.3) |
Treatment response, n (%) | – | – | 2 (100.0)b | 2 (7.7) |